Cargando…
Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
[Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compoun...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107917/ https://www.ncbi.nlm.nih.gov/pubmed/37077382 http://dx.doi.org/10.1021/acsmedchemlett.3c00008 |
_version_ | 1785026710849191936 |
---|---|
author | Gitlin-Domagalska, Agata Dębowski, Dawid Maciejewska, Aleksandra Samsonov, Sergey Maszota-Zieleniak, Martyna Ptaszyńska, Natalia Łęgowska, Anna Rolka, Krzysztof |
author_facet | Gitlin-Domagalska, Agata Dębowski, Dawid Maciejewska, Aleksandra Samsonov, Sergey Maszota-Zieleniak, Martyna Ptaszyńska, Natalia Łęgowska, Anna Rolka, Krzysztof |
author_sort | Gitlin-Domagalska, Agata |
collection | PubMed |
description | [Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compounds with the ability to inhibit furin’s proteolytic action are regarded as potential therapeutics. Here we took the combinatorial chemistry approach (library consisting of 2000 peptides) to obtain new, strong, and stable peptide furin inhibitors. The extensively studied trypsin inhibitor SFTI-1 was used as a leading structure. A selected monocylic inhibitor was further modified to finally yield five mono- or bicyclic furin inhibitors with values of K(i) in the subnanomolar range. Inhibitor 5 was the most active (K(i) = 0.21 nM) and significantly more proteolytically resistant than the reference furin inhibitor described in the literature. Moreover, it reduced furin-like activity in PANC-1 cell lysate. Detailed analysis of furin–inhibitor complexes using molecular dynamics simulations is also reported. |
format | Online Article Text |
id | pubmed-10107917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-101079172023-04-18 Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry Gitlin-Domagalska, Agata Dębowski, Dawid Maciejewska, Aleksandra Samsonov, Sergey Maszota-Zieleniak, Martyna Ptaszyńska, Natalia Łęgowska, Anna Rolka, Krzysztof ACS Med Chem Lett [Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compounds with the ability to inhibit furin’s proteolytic action are regarded as potential therapeutics. Here we took the combinatorial chemistry approach (library consisting of 2000 peptides) to obtain new, strong, and stable peptide furin inhibitors. The extensively studied trypsin inhibitor SFTI-1 was used as a leading structure. A selected monocylic inhibitor was further modified to finally yield five mono- or bicyclic furin inhibitors with values of K(i) in the subnanomolar range. Inhibitor 5 was the most active (K(i) = 0.21 nM) and significantly more proteolytically resistant than the reference furin inhibitor described in the literature. Moreover, it reduced furin-like activity in PANC-1 cell lysate. Detailed analysis of furin–inhibitor complexes using molecular dynamics simulations is also reported. American Chemical Society 2023-03-15 /pmc/articles/PMC10107917/ /pubmed/37077382 http://dx.doi.org/10.1021/acsmedchemlett.3c00008 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Gitlin-Domagalska, Agata Dębowski, Dawid Maciejewska, Aleksandra Samsonov, Sergey Maszota-Zieleniak, Martyna Ptaszyńska, Natalia Łęgowska, Anna Rolka, Krzysztof Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry |
title | Cyclic Peptidic
Furin Inhibitors Developed by Combinatorial
Chemistry |
title_full | Cyclic Peptidic
Furin Inhibitors Developed by Combinatorial
Chemistry |
title_fullStr | Cyclic Peptidic
Furin Inhibitors Developed by Combinatorial
Chemistry |
title_full_unstemmed | Cyclic Peptidic
Furin Inhibitors Developed by Combinatorial
Chemistry |
title_short | Cyclic Peptidic
Furin Inhibitors Developed by Combinatorial
Chemistry |
title_sort | cyclic peptidic
furin inhibitors developed by combinatorial
chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107917/ https://www.ncbi.nlm.nih.gov/pubmed/37077382 http://dx.doi.org/10.1021/acsmedchemlett.3c00008 |
work_keys_str_mv | AT gitlindomagalskaagata cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT debowskidawid cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT maciejewskaaleksandra cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT samsonovsergey cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT maszotazieleniakmartyna cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT ptaszynskanatalia cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT łegowskaanna cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry AT rolkakrzysztof cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry |